Cancer Clinical Trials
Saint Louis University School of Medicine faculty in hematology, oncology, and cellular therapy are committed to leadership in clinical research programs. Also as faculty of SSM Health Saint Louis University Hospital, our staff regularly conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.
Studies
GTM-103: Feasibility Study of Resection and Gamma Tile Followed by Concomitant External Beam Radiation Therapy (EBRT) and TMZ and Adjuvant TMZ in Newly Diagnosed GBM
GammaTile/GESTALT - John Dombrowski, M.D.
This study seeks to explore if GT, given its unique radiobiological and physical characteristics, may permit safe dose escalation and intensification and thereby provide a benefit to newly diagnosed GBM patients in terms of overall survival and local control when incorporated into the framework of the Stupp protocol.
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
AstraZeneca/eVOLVE-HNSCC (D798EC00001) - Maurice Willis, M.D.
A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1
AstraZeneca/TRITON (D419ML00003) - Maurice Willis, M.D.
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
GTM-102: A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
GammaTile/ROADS - John Dombrowski, M.D.
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Just-in-Time: Evaluating a Decision-based Algorithm for Plerixafor Usage in Stem Cell Mobilization in an Outpatient Transplant Center
Alexander Babic, M.D., Ph.D.
A study to evaluate stem cell collection times for patients seen at the Outpatient Bone Marrow Transplant Center at SSM Health Saint Louis University Hospital.
Reaching Rural Cancer Survivors who Smoke Using Test-Based Cessation Interventions
Alliance/A211901 - John Dombrowski, M.D., Ph.D.
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke to quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity Cancer - Temporary Enrollment Hold
NRG/HN006 - Sean Massa, M.D.
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
NRG/GU010 - Jeevin Shahi, M.D.
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness.
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (TELiMET)
Abbvie/M18-868 - Maurice Willis, M.D.
The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated.
Phase I/II dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as a single agent or in combination in advanced solid tumors
Merus/MCLA-158-CL01- Maurice Willis, M.D.
Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). **Currently only recruiting to metastatic colorectal cancer arm.**
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
ECOG-ACRIN/EA3191 - John Dombrowski, M.D.
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary).